Global trends of antimicrobial susceptibility to ceftaroline and ceftazidime–avibactam: a surveillance study from the ATLAS program (2012–2016)

Zhang, Hui; Xu, Yingchun; Jia, Peiyao; Zhu, Ying; Zhang, Ge; Zhang, Jingjia; Duan, Simeng; Kang, Wei; Wang, Tong; Jing, Ran; Cheng, Jingwei; Liu, Yali; Yang, Qiwen

doi:10.1186/s13756-020-00829-z

Antimicrobial Resistance & Infection Control

Table 3 In vitro susceptibilities of multi-drug resistant strains obtained from the ATLAS program, 2012–2016.

From: Global trends of antimicrobial susceptibility to ceftaroline and ceftazidime–avibactam: a surveillance study from the ATLAS program (2012–2016)

Organism/antibiotic	No. of isolates	MIC₅₀	MIC₉₀	MIC range	CLSI^a			EUCAST
Organism/antibiotic	No. of isolates	MIC₅₀	MIC₉₀	MIC range	S%	I%	R%	S%	I%	R%
CRECO
Ceftaroline	119	256	256	0.015–256	10.9	1.7	87.4	9.5	0	90.5
Ceftazidime–avibactam	119	0.5	256	0.03–256	72.3	0	27.7	40.5	0	59.5
Ceftazidime	119	64	256	0.12–256	22.7	4.2	73.1	11.9	2.4	85.7
Cefepime	119	32	32	0.12–32	8.4	16	75.6	0	2.4	97.6
Pip-taz	119	256	256	0.5–256	21.9	5.9	72.3	19.1	2.4	78.6
Doripenem	119	4	16	0.03–16	32.8	11.8	55.5	19.1	2.4	78.6
Imipenem	119	8	16	4–16	0	0	100	0	0	100
Meropenem	119	8	16	0.015–16	26.1	6.7	67.2	19.1	7.1	73.8
Levofloxacin	119	8	16	0.015–16	24.4	3.4	72.3	7.1	2.4	90.5
Tigecycline	119	0.25	1	0.03–4	98.3	1.7	0	88.1	7.1	4.8
Amikacin	119	8	64	1–64	78.2	5	16.8	59.5	7.1	33.3
Colistin	79	0.5	1	0.12–16	NA	NA	NA	96.3	0	3.7
Aztreonam	119	64	256	0.015–256	23.5	0.8	75.6	16.7	2.4	81
CRKPN
Ceftaroline	1418	256	256	0.06–256	0.6	0	99.4	0	0	100
Ceftazidime–avibactam	1418	1	256	0.015–256	85.6	0	14.4	83.6	0	16.4
Ceftazidime	1418	256	256	0.12–256	4	2.5	93.5	0.6	0.7	98.7
Cefepime	1418	32	32	0.12–32	3.5	8	88.6	0.4	0.6	99
Pip-taz	1418	256	256	2–256	1.5	1.1	97.4	0.3	0.1	99.6
Doripenem	1418	8	16	0.03–16	4.2	5.4	90.4	0.7	0.4	98.9
Imipenem	1418	16	16	4–16	0	0	100	0	0	100
Meropenem	1418	16	16	0.015–16	2.9	4	93.1	0.8	3.9	95.3
Levofloxacin	1418	8	16	0.03–16	12.7	3.5	83.9	3.1	1.6	95.2
Tigecycline	1418	1	2	0.06–16	92.6	6.3	1.1	74.7	17.1	8.2
Amikacin	1418	16	64	0.25–64	52.1	28.1	19.8	30.3	13.2	56.6
Colistin	1046	1	16	0.06–16	NA	NA	NA	74.2	0	25.8
Aztreonam	1418	256	256	0.03–256	4.4	0.4	95.1	2.7	0.2	97.1
CRECL
Ceftaroline	149	256	256	0.06–256	4.7	0.7	94.6	1.6	0	98.4
Ceftazidime–avibactam	149	128	256	0.06–256	42.3	0	57.7	21.9	0	78.1
Ceftazidime	149	256	256	0.12–256	8.7	1.3	89.9	1.6	1.6	96.9
Cefepime	149	32	32	0.12–32	14.8	10.7	74.5	4.7	0	95.3
Pip-taz	149	256	256	2–256	10.1	5.4	84.6	1.6	1.6	96.9
Doripenem	149	8	16	0.06–16	14.1	6.7	79.2	0	0	100
Imipenem	149	8	16	4–16	0	0	100	0	0	100
Meropenem	149	8	16	0.03–16	14.1	12.1	73.8	1.6	17.2	81.3
Levofloxacin	149	4	16	0.03–16	43.6	7.4	49	17.2	4.7	78.1
Tigecycline	149	1	4	0.12–8	83.9	14.1	2	59.4	15.6	25
Amikacin	149	4	64	0.5–64	80.5	5.4	14.1	60.9	7.8	31.3
Colistin	118	0.5	1	0.12–16	NA	NA	NA	93.8	0	6.3
Aztreonam	149	64	256	0.06–256	24.2	2	73.8	18.8	6.3	75
CRPAE
Ceftaroline	4546	128	256	0.015–256	NA	NA	NA	NA	NA	NA
Ceftazidime–avibactam	4546	4	64	0.015–256	74.5	0	25.5	70.6	0	29.4
Ceftazidime	4546	16	128	0.12–256	46.6	8.2	45.3	41.4	0	58.6
Cefepime	4546	16	32	0.25–32	47.2	23.2	29.6	41.5	0	58.6
Pip-taz	4546	64	256	0.25–256	34.7	24.8	40.5	29.4	0	70.7
Doripenem	4545	8	16	0.03–16	15.1	22.8	62.1	1.8	5.9	92.3
Imipenem	4546	16	16	8–16	0	0	100	0	0	100
Meropenem	4546	16	16	0.06–16	11.7	15.4	72.9	4.9	33.5	61.7
Levofloxacin	4546	8	16	0.015–16	36	10	54	22.1	0	77.9
Tigecycline	4546	16	16	0.03–16	NA	NA	NA	NA	NA	NA
Amikacin	4546	8	64	0.25–64	72.8	7.3	19.9	60.5	9.2	30.4
Colistin	3521	1	2	0.06–16	96.4	0	3.6	96.6	0	3.4
Aztreonam	4546	16	128	0.06–256	30.7	21	48.3	1.1	46.6	52.4
CRABA
Ceftaroline	2318	256	256	2–256	NA	NA	NA	NA	NA	NA
Ceftazidime–avibactam	2318	64	256	0.06–256	NA	NA	NA	NA	NA	NA
Ceftazidime	2318	128	256	1–256	5.1	2.3	92.7	NA	NA	NA
Cefepime	2318	32	32	0.25–32	3.6	10.7	85.7	NA	NA	NA
Pip-taz	2318	256	256	4–256	0.4	0.7	99	NA	NA	NA
Doripenem	2318	8	16	0.5–16	0.2	0.4	99.4	0	0	100
Imipenem	2318	16	16	8–16	0	0	100	0	0	100
Meropenem	2318	16	16	1–16	0.1	0.5	99.4	0	1.9	98.1
Levofloxacin	2318	8	16	0.06–16	3.8	11.4	84.9	1.4	0.6	98
Tigecycline	2318	1	4	0.03–16	NA	NA	NA	NA	NA	NA
Amikacin	2318	64	64	0.25–64	19.3	7.8	73	16.4	2.7	80.9
Colistin	1552	1	2	0.12–16	92.1	0	7.9	92	0	8
Aztreonam	2318	64	256	2–256	NA	NA	NA	NA	NA	NA
MRSA
Ceftaroline	30100	0.5	2	0.03–64	89.0	10.3	0.7	NA	NA	NA
Ceftazidime–avibactam	30100	64	64	2–64	NA	NA	NA	NA	NA	NA
Ceftazidime	30100	64	64	1–64	NA	NA	NA	NA	NA	NA
Pip-taz	30100	32	32	0.12–32	NA	NA	NA	NA	NA	NA
Doripenem	30100	2	8	0.008–8	NA	NA	NA	NA	NA	NA
Meropenem	30100	4	16	0.015–16	NA	NA	NA	NA	NA	NA
Levofloxacin	30100	4	8	0.015–8	32.4	0.5	67.1	NA	NA	NA
Moxifloxacin	30100	2	4	0.008–8	32.6	3.9	63.5	NA	NA	NA
Minocycline	30100	0.12	8	0.12–16	89.4	5.3	5.4	NA	NA	NA
Tigecycline	30100	0.12	0.5	0.015–4	98.5	1.5	0	NA	NA	NA
Clindamycin	30100	0.12	8	0.03–8	61	0.3	38.7	NA	NA	NA
Erythromycin	30100	8	16	0.12–16	29.7	2.5	67.8	NA	NA	NA
Vancomycin	30100	1	2	0.25–4	100	0	0	NA	NA	NA
Teicoplanin	30100	1	2	0.12–32	100	0	0	NA	NA	NA
Linezolid	30100	2	2	0.5–16	100	0	0	NA	NA	NA
Daptomycin	30100	0.5	1	0.06–4	99.7	0.3	0	NA	NA	NA
Gentamicin	18616	1	64	0.06–64	78.2	0.9	21	NA	NA	NA
Trimethoprim sulfa	18616	0.25	1	0.25–8	95.6	0	4.4	NA	NA	NA
Oxacillin	30100	4	8	4–8	0	0	100	NA	NA	NA
PRSP
Ceftaroline	1925	0.12	0.25	0.008–32	98.2	1.8	0	86.8	0	13.2
Ceftazidime–avibactam	1925	16	64	1–128	NA	NA	NA	NA	NA	NA
Ceftazidime	1925	16	64	1–128	NA	NA	NA	NA	NA	NA
Penicillin	1925	4	8	2–16	0	0	100	0	0	100
Doripenem	1925	1	2	0.015–8	89.4	10.6	0	81.1	0	18.9
Meropenem	1925	1	2	0.008–2	3.4	32.3	64.3	100	0	0
Levofloxacin	1925	1	2	0.12–16	95.3	0.5	4.2	94.1	0	6
Moxifloxacin	1925	0.12	0.25	0.03–8	95.7	1.5	2.8	94.6	0	5.4
Minocycline	1925	4	4	0.03–4	28.5	13.2	58.3	18.8	3	78.2
Tigecycline	1925	0.03	0.03	0.008–2	99.8	0.2	0	NA	NA	NA
Clindamycin	1925	2	2	0.008–2	32.6	0.3	67.2	24.3	0	75.7
Erythromycin	1925	2	2	0.008–2	13.9	0.2	86	10.9	0.1	89
Vancomycin	1925	0.5	0.5	0.015–2	99.9	0.1	0	100	0	0
Linezolid	1925	1	1	0.06–2	100	0	0	100	0	0

CLSI Clinical Laboratory and Standards Institute, EUCAST European Committee on Antimicrobial Susceptibility Testing, CRECO Carbapenem-resistant Escherichia coli, CRKPN Carbapenem-resistant Klebsiella pneumonia, CRECL Carbapenem-resistant Enterobacter cloacae, CRPAE Carbapenem-resistant Pseudomonas aeruginosa, CRABA Carbapenem-resistant Acinetobacter baumannii, MRSA Methicillin-resistant Staphylococcus aureus, PRSP Penicillin-resistant Streptococcus pneumonia, NA not applicable
^aCefepime CLSI susceptibility for Enterobacteriaceae adopted the susceptible, susceptible-dose-dependent, and resistant categories

Back to article page

ISSN: 2047-2994

Contact us

General enquiries: journalsubmissions@springernature.com